WallStSmart

Canopy Growth Corp (CGC)vsTakeda Pharmaceutical Co Ltd ADR (TAK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Takeda Pharmaceutical Co Ltd ADR generates 1583060% more annual revenue ($4.51T vs $284.60M). TAK leads profitability with a -3.4% profit margin vs -92.4%. TAK earns a higher WallStSmart Score of 57/100 (C).

CGC

Avoid

34

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 4/9Altman Z: -12.96

TAK

Buy

57

out of 100

Grade: C

Growth: 6.7Profit: 4.0Value: 6.7Quality: 5.0
Piotroski: 4/9Altman Z: 1.20

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CGC1 strengths · Avg: 10.0/10
Price/BookValuation
0.8x10/10

Reasonable price relative to book value

TAK4 strengths · Avg: 9.8/10
PEG RatioValuation
0.4510/10

Growing faster than its price suggests

Price/BookValuation
1.2x10/10

Reasonable price relative to book value

EPS GrowthGrowth
330.2%10/10

Earnings expanding 330.2% YoY

Market CapQuality
$55.95B9/10

Large-cap with strong market position

Areas to Watch

CGC4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$405.86M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-41.0%2/10

ROE of -41.0% — below average capital efficiency

Free Cash FlowQuality
$-19.36M2/10

Negative free cash flow — burning cash

TAK4 concerns · Avg: 2.8/10
Revenue GrowthGrowth
3.9%4/10

3.9% revenue growth

Return on EquityProfitability
2.5%3/10

ROE of 2.5% — below average capital efficiency

Free Cash FlowQuality
$-26.01B2/10

Negative free cash flow — burning cash

Altman Z-ScoreHealth
1.202/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : CGC

The strongest argument for CGC centers on Price/Book.

Bull Case : TAK

The strongest argument for TAK centers on PEG Ratio, Price/Book, EPS Growth. PEG of 0.45 suggests the stock is reasonably priced for its growth.

Bear Case : CGC

The primary concerns for CGC are EPS Growth, Market Cap, Return on Equity.

Bear Case : TAK

The primary concerns for TAK are Revenue Growth, Return on Equity, Free Cash Flow.

Key Dynamics to Monitor

CGC carries more volatility with a beta of 2.42 — expect wider price swings.

CGC is growing revenue faster at 9.6% — sustainability is the question.

CGC generates stronger free cash flow (-19M), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

TAK scores higher overall (57/100 vs 34/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Canopy Growth Corp

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Canopy Growth Corporation is engaged in the production, distribution and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. The company is headquartered in Smiths Falls, Canada.

Takeda Pharmaceutical Co Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.

Want to dig deeper into these stocks?